JP2009509962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009509962A5 JP2009509962A5 JP2008532431A JP2008532431A JP2009509962A5 JP 2009509962 A5 JP2009509962 A5 JP 2009509962A5 JP 2008532431 A JP2008532431 A JP 2008532431A JP 2008532431 A JP2008532431 A JP 2008532431A JP 2009509962 A5 JP2009509962 A5 JP 2009509962A5
- Authority
- JP
- Japan
- Prior art keywords
- capsule
- capsule according
- calcium
- sodium
- cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 5
- 235000010216 calcium carbonate Nutrition 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 229940032147 starch Drugs 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- -1 dextrate Polymers 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 239000000395 magnesium oxide Substances 0.000 claims description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 4
- 235000012245 magnesium oxide Nutrition 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 235000010419 agar Nutrition 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 3
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 3
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 3
- 239000000832 lactitol Substances 0.000 claims description 3
- 235000010448 lactitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
- 229960003451 lactitol Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 3
- 239000001095 magnesium carbonate Substances 0.000 claims description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 239000004135 Bone phosphate Substances 0.000 claims description 2
- QQXDYWHKPKEBJU-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCC[Na] Chemical compound CCCCCCCCCCCCCCCCCC[Na] QQXDYWHKPKEBJU-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 2
- 235000001465 calcium Nutrition 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 239000004927 clay Substances 0.000 claims description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 229920001971 elastomer Polymers 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229960000540 polacrilin potassium Drugs 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 239000008109 sodium starch glycolate Substances 0.000 claims description 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 25
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 230000003176 fibrotic effect Effects 0.000 claims 4
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000009151 chronic rhinitis Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 229940069328 povidone Drugs 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 201000000054 Coronary Restenosis Diseases 0.000 claims 1
- 206010056489 Coronary artery restenosis Diseases 0.000 claims 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 208000031737 Tissue Adhesions Diseases 0.000 claims 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000010234 sodium benzoate Nutrition 0.000 claims 1
- 239000004299 sodium benzoate Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940096516 dextrates Drugs 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000002362 mulch Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72025705P | 2005-09-22 | 2005-09-22 | |
| US60/720,257 | 2005-09-22 | ||
| PCT/US2006/037057 WO2007038315A2 (en) | 2005-09-22 | 2006-09-22 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012180913A Division JP5715101B2 (ja) | 2005-09-22 | 2012-08-17 | ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009509962A JP2009509962A (ja) | 2009-03-12 |
| JP2009509962A5 true JP2009509962A5 (https=) | 2015-11-05 |
| JP5837732B2 JP5837732B2 (ja) | 2015-12-24 |
Family
ID=37898745
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532431A Active JP5837732B2 (ja) | 2005-09-22 | 2006-09-22 | ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物 |
| JP2012180913A Active JP5715101B2 (ja) | 2005-09-22 | 2012-08-17 | ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物 |
| JP2014129551A Pending JP2014169341A (ja) | 2005-09-22 | 2014-06-24 | ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012180913A Active JP5715101B2 (ja) | 2005-09-22 | 2012-08-17 | ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物 |
| JP2014129551A Pending JP2014169341A (ja) | 2005-09-22 | 2014-06-24 | ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US7988994B2 (https=) |
| EP (2) | EP1940364B2 (https=) |
| JP (3) | JP5837732B2 (https=) |
| KR (3) | KR101645069B1 (https=) |
| CN (3) | CN103393607A (https=) |
| AP (2) | AP2655A (https=) |
| AU (2) | AU2006295440B2 (https=) |
| BR (1) | BRPI0616324A2 (https=) |
| CA (2) | CA2620380C (https=) |
| CU (1) | CU20080043A7 (https=) |
| CY (1) | CY1115544T1 (https=) |
| DK (1) | DK1940364T4 (https=) |
| EA (1) | EA030093B1 (https=) |
| EC (1) | ECSP088394A (https=) |
| ES (1) | ES2496144T5 (https=) |
| GE (1) | GEP20115303B (https=) |
| IL (2) | IL189273A (https=) |
| MA (1) | MA29875B1 (https=) |
| MX (1) | MX2008003882A (https=) |
| NO (1) | NO345131B1 (https=) |
| NZ (3) | NZ591443A (https=) |
| PL (1) | PL1940364T5 (https=) |
| PT (1) | PT1940364E (https=) |
| SI (1) | SI1940364T2 (https=) |
| TN (1) | TNSN08136A1 (https=) |
| UA (2) | UA115861C2 (https=) |
| WO (1) | WO2007038315A2 (https=) |
| ZA (1) | ZA200802237B (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100891887B1 (ko) | 2001-01-29 | 2009-04-03 | 시오노기세이야쿠가부시키가이샤 | 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서 함유하는의약 제제 |
| ES2524922T3 (es) | 2005-05-10 | 2014-12-15 | Intermune, Inc. | Derivados de piridona para modular el sistema de proteína cinasa activada por estrés |
| NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
| SI2124945T1 (sl) | 2006-12-18 | 2011-08-31 | Intermune Inc | Postopek dajanja terapije s pirfenidonom pacientu |
| US20080242293A1 (en) * | 2007-04-02 | 2008-10-02 | Cequint, Inc. | System and method for providing caller id name display in wireless communications system |
| WO2008147169A2 (es) * | 2007-05-29 | 2008-12-04 | Cell Therapy Technology, S.A. De C.V. | Microemolsion conteniendo pirfenidona |
| JP5587184B2 (ja) | 2007-06-20 | 2014-09-10 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 繊維症阻害剤としての置換ｎ−アリールピリジノン |
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| EP2262501B1 (en) * | 2008-03-07 | 2014-08-13 | Solanan, Inc. | Treatment of sepsis with 5-ethyl-1-phenyl-2(1h)-pyridone |
| CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
| US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
| AU2010206543A1 (en) * | 2009-01-26 | 2011-07-07 | Intermune, Inc. | Methods for treating acute myocardial infarctions and associated disorders |
| EP2408905B1 (en) | 2009-03-16 | 2017-05-10 | Pangu Biopharma Limited | Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities |
| US7816383B1 (en) | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
| CN101912395B (zh) * | 2010-08-12 | 2012-09-26 | 北京凯因科技股份有限公司 | 一种含吡非尼酮的药物组合物及其制备方法 |
| JP6021117B2 (ja) | 2011-01-31 | 2016-11-02 | ジェノア ファーマシューティカルズ，インク． | エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用 |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| JP2014507474A (ja) | 2011-03-08 | 2014-03-27 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換ｎ−アリールピリジノン |
| CN102670632A (zh) * | 2011-03-12 | 2012-09-19 | 赵海静 | 吡非尼酮在抑制皮肤瘢痕形成的医药用途 |
| MX2011007675A (es) * | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| US20130149383A1 (en) * | 2011-12-12 | 2013-06-13 | Cory Berkland | Sustained release particle formulations of guaifenesin |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| CA2819967C (en) * | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CN105378075B (zh) | 2013-03-15 | 2022-04-05 | Atyr 医药公司 | 组氨酰-trna合成酶-fc缀合物 |
| EP2968292A4 (en) | 2013-03-15 | 2016-11-23 | Intermune Inc | METHOD FOR IMPROVING MICROVASCULAR INTEGRITY |
| NZ719865A (en) * | 2013-12-13 | 2022-07-29 | Novartis Ag | A pharmaceutical dosage form produced from the wet granulation of 3-(2,6-dichloro-3,5- dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methylurea |
| NZ760541A (en) | 2014-01-10 | 2022-08-26 | Avalyn Pharma Inc | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| WO2015156649A1 (ko) * | 2014-04-11 | 2015-10-15 | 주식회사 젬백스앤카엘 | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| WO2016059815A1 (ja) * | 2014-10-15 | 2016-04-21 | 安良太 吾妻 | 癌化学予防薬 |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| TWI745396B (zh) | 2016-07-12 | 2021-11-11 | 日商鹽野義製藥股份有限公司 | 吸入用醫藥組成物 |
| KR102051559B1 (ko) * | 2016-12-09 | 2019-12-05 | 재단법인 아산사회복지재단 | 섬유증의 진단 또는 치료를 위한 스테아르산의 용도 |
| KR20180100869A (ko) * | 2017-03-02 | 2018-09-12 | 영진약품 주식회사 | 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법 |
| CN110536694A (zh) * | 2017-04-20 | 2019-12-03 | Atyr 医药公司 | 用于治疗肺部炎症的组合物和方法 |
| MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
| ES2900457T3 (es) * | 2018-01-12 | 2022-03-17 | Tiefenbacher Alfred E Gmbh & Co Kg | Formulación de comprimidos y cápsulas que contienen pirfenidona |
| US20210205253A1 (en) * | 2018-05-31 | 2021-07-08 | The Asan Foundation | Use Of Stearic Acid For Preventing Or Treating Pulmonary Fibrosis |
| US20210267955A1 (en) * | 2018-06-29 | 2021-09-02 | Zenvision Pharma Llp | Low dose oral pharmaceutical composition of pirfenidone or salt thereof |
| WO2020115774A1 (en) | 2018-12-06 | 2020-06-11 | Cipla Limited | High drug load extended release formulations |
| KR20220109439A (ko) | 2019-12-04 | 2022-08-04 | 이도르시아 파마슈티컬스 리미티드 | 섬유증 질환의 치료에서 사용하기 위한 아제티딘 lpa1 수용체 길항제와 피르페니돈 및/또는 닌테다닙의 조합 |
| EP4122471A4 (en) * | 2020-02-06 | 2025-02-19 | Ribomic Inc | THERAPEUTIC AGENT FOR SUBRETINAL HYPERREFLECTIVE MATERIAL OR RETINAL DISORDERS ASSOCIATED WITH SUBRETINAL HYPERREFLECTIVE MATERIAL |
| EP4117659A4 (en) * | 2020-03-13 | 2024-04-03 | Puretech Lyt 100, Inc. | Methods of treating respiratory disease with deupirfenidone |
| WO2021198253A1 (en) | 2020-04-01 | 2021-10-07 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions |
| US20230117397A1 (en) * | 2020-04-14 | 2023-04-20 | Excalibur Pharmaceuticals, Inc. | Pirfenidone for coronavirus treatment |
| JP7490813B2 (ja) * | 2020-04-22 | 2024-05-27 | ユンジン ファーム．カンパニー、リミテッド | 安全性と安定性が改善されたピルフェニドンを含む腸溶性製剤およびその製造方法 |
| KR102764240B1 (ko) | 2021-01-25 | 2025-02-11 | 주식회사 나이벡 | 섬유화 예방 및 치료용 펩타이드 |
| CN117224429B (zh) * | 2023-11-15 | 2024-02-06 | 南京天纵易康生物科技股份有限公司 | 一种含羟乙基纤维素作为崩解剂的烟酰胺/肽类固液分离护肤组合物及其制备方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
| US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
| CA1049411A (en) | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | N-substituted pyridone and general method for preparing pyridones |
| JPH02215719A (ja) | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
| US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| JPH08510251A (ja) * | 1993-05-07 | 1996-10-29 | ビー マーゴリン、ソロモン | 線維症の病変の修復と予防のための組成物および方法 |
| US5591766A (en) | 1993-12-03 | 1997-01-07 | Cheil Foods & Chemicals, Inc. | Solid oral formulations of pyridone carboxylic acids |
| US6090822A (en) | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
| US5962478A (en) * | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
| EP0866656B1 (en) | 1995-09-19 | 2007-04-25 | MARGOLIN, Solomon B. | Use of n-substituted pyridones as tumor necrosis factor alpha inhibitors |
| AU4278301A (en) * | 2000-03-27 | 2001-10-08 | Kyowa Hakko Kogyo Co. Ltd. | Easy-to-take granule |
| KR100891887B1 (ko) | 2001-01-29 | 2009-04-03 | 시오노기세이야쿠가부시키가이샤 | 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서 함유하는의약 제제 |
| JP4280074B2 (ja) * | 2001-04-25 | 2009-06-17 | 大正製薬株式会社 | マルチプルユニット型徐放性錠剤 |
| US7007089B2 (en) * | 2001-06-06 | 2006-02-28 | Akarnai Technologies, Inc. | Content delivery network map generation using passive measurement data |
| US7512702B1 (en) * | 2002-03-19 | 2009-03-31 | Cisco Technology, Inc. | Method and apparatus providing highly scalable server load balancing |
| US7139840B1 (en) * | 2002-06-14 | 2006-11-21 | Cisco Technology, Inc. | Methods and apparatus for providing multiple server address translation |
| AU2003262811A1 (en) | 2002-08-27 | 2004-03-19 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
| EP1551369A4 (en) * | 2002-08-28 | 2007-05-09 | Intermune Inc | COMBINATION THERAPY FOR THE TREATMENT OF FIBROTIC DISEASES |
| US7159034B1 (en) * | 2003-03-03 | 2007-01-02 | Novell, Inc. | System broadcasting ARP request from a server using a different IP address to balance incoming traffic load from clients via different network interface cards |
| HRP20050902A2 (en) * | 2003-03-31 | 2005-12-31 | Pliva-Lachema A.S. | Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof |
| US20050008691A1 (en) * | 2003-05-14 | 2005-01-13 | Arturo Siles Ortega | Bicalutamide compositions |
| CN101039957A (zh) | 2003-05-16 | 2007-09-19 | 因特缪恩公司 | 合成的趋化因子受体配体及其使用方法 |
| US20070092488A1 (en) | 2003-05-16 | 2007-04-26 | Intermune Inc. | Methods of treating idiopathic pulmonary fibrosis |
| CA2531116A1 (en) * | 2003-07-01 | 2005-01-20 | Michael Hawley | Diffusion layer modulated solids |
| US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| JP4614884B2 (ja) | 2003-11-14 | 2011-01-19 | シャンハイ ゲノミックス インク | ピリドンの誘導体とその使用 |
| SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8642079B2 (en) * | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
| US7584435B2 (en) * | 2004-03-03 | 2009-09-01 | Omniture, Inc. | Web usage overlays for third-party web plug-in content |
| AU2006276246B2 (en) | 2005-07-25 | 2012-09-27 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis C virus replication |
| NZ591443A (en) † | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
-
2005
- 2005-09-22 NZ NZ591443A patent/NZ591443A/xx not_active IP Right Cessation
-
2006
- 2006-09-22 UA UAA201203869A patent/UA115861C2/uk unknown
- 2006-09-22 US US12/067,712 patent/US7988994B2/en active Active
- 2006-09-22 CN CN2013103433683A patent/CN103393607A/zh active Pending
- 2006-09-22 KR KR1020137022095A patent/KR101645069B1/ko active Active
- 2006-09-22 EA EA200800881A patent/EA030093B1/ru active Protection Beyond IP Right Term
- 2006-09-22 UA UAA200805048A patent/UA99433C2/ru unknown
- 2006-09-22 AP AP2008004390A patent/AP2655A/xx active
- 2006-09-22 EP EP06815221.4A patent/EP1940364B2/en active Active
- 2006-09-22 CN CN201410057564.9A patent/CN103735530A/zh active Pending
- 2006-09-22 KR KR1020087006806A patent/KR20080046673A/ko not_active Ceased
- 2006-09-22 GE GEAP200610558A patent/GEP20115303B/en unknown
- 2006-09-22 DK DK06815221.4T patent/DK1940364T4/da active
- 2006-09-22 PT PT68152214T patent/PT1940364E/pt unknown
- 2006-09-22 JP JP2008532431A patent/JP5837732B2/ja active Active
- 2006-09-22 AP AP2012006231A patent/AP2012006231A0/xx unknown
- 2006-09-22 CN CNA2006800348742A patent/CN101267810A/zh active Pending
- 2006-09-22 ES ES06815221T patent/ES2496144T5/es active Active
- 2006-09-22 MX MX2008003882A patent/MX2008003882A/es active IP Right Grant
- 2006-09-22 EP EP11007850A patent/EP2431025A1/en not_active Withdrawn
- 2006-09-22 CU CU20080043A patent/CU20080043A7/es unknown
- 2006-09-22 ZA ZA200802237A patent/ZA200802237B/xx unknown
- 2006-09-22 KR KR1020147004496A patent/KR101675651B1/ko active Active
- 2006-09-22 SI SI200631819T patent/SI1940364T2/sl unknown
- 2006-09-22 AU AU2006295440A patent/AU2006295440B2/en not_active Revoked
- 2006-09-22 CA CA2620380A patent/CA2620380C/en active Active
- 2006-09-22 NZ NZ565957A patent/NZ565957A/en not_active IP Right Cessation
- 2006-09-22 NZ NZ600129A patent/NZ600129A/en not_active IP Right Cessation
- 2006-09-22 CA CA2762013A patent/CA2762013C/en active Active
- 2006-09-22 WO PCT/US2006/037057 patent/WO2007038315A2/en not_active Ceased
- 2006-09-22 BR BRPI0616324-6A patent/BRPI0616324A2/pt not_active Application Discontinuation
- 2006-09-22 PL PL06815221.4T patent/PL1940364T5/pl unknown
-
2008
- 2008-02-04 IL IL189273A patent/IL189273A/en active IP Right Grant
- 2008-02-12 NO NO20080759A patent/NO345131B1/no unknown
- 2008-03-19 TN TNP2008000136A patent/TNSN08136A1/en unknown
- 2008-04-17 MA MA30855A patent/MA29875B1/fr unknown
- 2008-04-22 EC EC2008008394A patent/ECSP088394A/es unknown
-
2009
- 2009-04-17 US US12/426,182 patent/US7767225B2/en active Active
-
2011
- 2011-04-05 AU AU2011201520A patent/AU2011201520B2/en not_active Revoked
- 2011-06-16 US US13/162,048 patent/US8383150B2/en active Active
-
2012
- 2012-08-17 JP JP2012180913A patent/JP5715101B2/ja active Active
-
2013
- 2013-02-25 US US13/776,079 patent/US8753679B2/en active Active
-
2014
- 2014-05-07 US US14/271,720 patent/US20140242159A1/en not_active Abandoned
- 2014-06-24 JP JP2014129551A patent/JP2014169341A/ja active Pending
- 2014-09-10 CY CY20141100731T patent/CY1115544T1/el unknown
-
2015
- 2015-07-09 IL IL239868A patent/IL239868A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009509962A5 (https=) | ||
| CA2620380A1 (en) | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | |
| JP2018507200A5 (https=) | ||
| US11673877B2 (en) | Niraparib compositions | |
| JP2017505330A5 (https=) | ||
| US20090186086A1 (en) | Solid multilayer oral dosage forms | |
| DK2588086T3 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING 4-AMINO-5-FLUORO-3- [6- (4-METHYLPIPERAZIN-1-YL) -1H-BENZIMIDAZOL-2-YL] -1H-QUINOLIN-2-ON-LACTATE MONOHYDRATE | |
| JP2007091758A5 (https=) | ||
| JP2015518885A5 (https=) | ||
| JP2017528507A5 (https=) | ||
| JP2017525712A5 (https=) | ||
| HRP20200605T1 (hr) | Farmaceutske kompozicije za liječenje inflamatornih poremećaja | |
| JP2020523335A5 (https=) | ||
| JP2013147470A (ja) | 口腔内崩壊錠 | |
| JP2018503611A5 (https=) | ||
| NO20091644L (no) | Hurtig desintegrerende, lyofiliserte orale formuleringer av en trombinreseptorantagonist | |
| WO2014142607A1 (ko) | 약제학적 복합제제 | |
| DK2986281T3 (en) | ORAL FORMULATION FOR TREATMENT OF CARDIOVASCULAR DISEASES | |
| JP2008500287A5 (https=) | ||
| JP2013544795A5 (https=) | ||
| ES2693156T3 (es) | Comprimido de liberación sostenida que contiene levodropropizina y método para prepararlo | |
| WO2012060786A2 (en) | Cefpodoxime proxetil formulations comprising viscosity agent | |
| WO2011093828A2 (en) | Solid dosage forms comprising cefprozil | |
| EP2571484A2 (en) | Effervescent formulations | |
| JP5525453B2 (ja) | 医薬組成物 |